A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge

To curb the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), multiple platforms have been employed toward a safe and highly effective vaccine. Here, we develop a novel cell-based vaccine candidate, namely K562-S, by utilizing...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiangchuan, Ding, Longfei, Cao, Kangli, Peng, Haoran, Gu, Chenjian, Li, Yutang, Li, Duoduo, Dong, Lanlan, Hong, Xiujing, Wang, Xiangwei, Fu, Meilan, Qiu, Chenli, Zhu, Cuisong, Zhang, Ziling, Song, Shu, Wang, Chenguang, Jiang, Zhengfan, Xie, Youhua, Qi, Zhongtian, Zhao, Chen, Zhao, Ping, Zhang, Xiaoyan, Xu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366622/
https://www.ncbi.nlm.nih.gov/pubmed/34304724
http://dx.doi.org/10.1080/22221751.2021.1957400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366622/
https://www.ncbi.nlm.nih.gov/pubmed/34304724
http://dx.doi.org/10.1080/22221751.2021.1957400

Ejemplares similares